EUCTR2008-002353-20-BE进行中（未招募）1 期
an open-label study to evaluate safety and efficacy of 750 mg intravenous mepolizumab in subjects with steroid refractory eosinophilic cystitis
Z Gasthuisberg0 个研究点目标入组 1 人开始时间: 2008年5月28日最近更新:
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 1
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- Male
入选标准
- •steroid-dependent eosinophilic cystitis
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •life threatening or other serious illness
- •serum creatinine > 3 ULN
- •AST or ALT > 5 ULN
- •platelets count < 50000/µL
- •left ventricular ejection fraction < 20%
- •positive pregnancy test
研究者
相似试验
招募中
3 期
An open-label study to assess safety and efficacy of SZC in paediatric patients with hyperkalaemia2023-508455-38-00AstraZeneca AB58
进行中（未招募）
1 期
A study to investigate increasing doses of Sodium Zirconium Cyclosilicate (SZC) in children under 18 years old who have high blood potassium levels (Hyperkalaemia ). This research is to find out if SZC will work and be safe for the treatment of hyperkalaemia in children under 18 years of age.EUCTR2018-001331-48-PLAstraZeneca AB140
招募中
1 期
An open-label study to assess safety and efficacy of SZC in paediatric patients with hyperkalaemiaHyperkalaemiaMedDRA version: 21.1Level: LLTClassification code: 10020647Term: Hyperkalemia Class: 10027433CTIS2023-508455-38-00AstraZeneca AB140
招募中
3 期
An open-label study to assess safety and efficacy of SZC in paediatric patients with hyperkalaemiaHyperkalaemiaJPRN-jRCT2031220173Ageishi Yuji3
进行中（未招募）
不适用
An open-label study evaluating safety and efficacy of recombinant human nerve growth factor (rhNGF) eye drops at different doses in patients with Dry EyeEUCTR2013-004271-12-ATDompé s.p.a